ARCHIVES

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

This article is from The Cancer Letter archive.

Vol. 38 No. 14 | April 6, 2012

Download PDF Visit The Full Archive

Related Articles

Science Policy: Silicone Breast Implants Don’t Cause Disease

June 25, 1999

Irinotecan And Carboplatin Improve Response In NSCLC

June 24, 2005

Three Institutes To Test BioMicro’s Microarray Product. GlycoDesign Allowed Patent For Cancer Drug GD0039.

March 1, 2002

Clinical Trials Approved By NCI CTEP Last Month

March 25, 2011

In Brief: House Appropriations Committee Gives NCI $725 Million, Smallest Increase Since 1970

June 1, 1975

Michigan’s Zhang Wins “Protein Science Olympics”

January 14, 2011